Provided by Tiger Trade Technology Pte. Ltd.

ENGENE HOLDINGS INC

1.94
-0.0400-2.02%
Post-market: 1.91-0.0300-1.55%19:30 EDT
Volume:692.75K
Turnover:1.38M
Market Cap:129.95M
PE:-0.96
High:2.02
Open:2.00
Low:1.93
Close:1.98
52wk High:12.25
52wk Low:1.40
Shares:66.98M
Float Shares:32.73M
Volume Ratio:0.71
T/O Rate:2.12%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.0205
EPS(LYR):-2.2947
ROE:-60.50%
ROA:-31.99%
PB:0.56
PE(LYR):-0.85

Loading ...

enGene Q2 FY26 net loss widens to USD 30.23 million

Reuters
·
Jun 15

enGene Therapeutics Inc: CFO Ryan Daws to Depart From Co, Effective July 15, 2026

THOMSON REUTERS
·
Jun 15

enGene Therapeutics - Implements Workforce Reduction of About 50% in June 2026

THOMSON REUTERS
·
Jun 15

enGene Reports Second Quarter 2026 Financial Results and Provides Business Update

THOMSON REUTERS
·
Jun 15

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Jun 12

enGene Therapeutics held annual shareholder meeting

Reuters
·
Jun 11

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Jun 10

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Jun 08

enGene Therapeutics Inc expected to post a loss of 47 cents a share - Earnings Preview

Reuters
·
May 29

enGene Holdings Is Maintained at Neutral by UBS

Dow Jones
·
May 15

enGene price target lowered to $2 from $9 at UBS

TIPRANKS
·
May 14

UBS Adjusts enGene Price Target to $2 From $9, Maintains Neutral Rating

MT Newswires Live
·
May 14

enGene Therapeutics (ENGN) Is Down 80.6% After Mixed Phase 2 Bladder Cancer Data Update - What's Changed

Simply Wall St.
·
May 09

enGene Therapeutics announces annual shareholder meeting webcast

Reuters
·
May 09

Citizens Downgrades enGene to Market Perform From Market Outperform

MT Newswires Live
·
May 08

Piper Sandler Downgrades enGene Holdings to Neutral From Overweight, Adjusts Price Target to $4 From $7

MT Newswires Live
·
May 08

enGene Holdings Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
May 08

enGene Holdings (ENGN) Gets a Buy from H.C. Wainwright

TIPRANKS
·
May 08

enGene Therapeutics Inc. : Wells Fargo Cuts Target Price to $2 From $25

THOMSON REUTERS
·
May 08

enGene Holdings Cut to Neutral From Overweight by Piper Sandler

Dow Jones
·
May 08